Trimebutine Maleate

PreclinicalSmall molecule

Trimebutine Maleate is one of 3 small molecule programs targeting Upper Gastrointestinal Bleeding. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Upper Gastrointestinal BleedingNot yet recruiting

Upper Gastrointestinal BleedingPreclinical

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Upper Gastrointestinal Bleeding

#DrugCompanyPhaseTrials

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 2

Keverprazan

NNanjing First Hospital, Nanjing Medical University

Preclinical

1 3

Trimebutine Maleate

XXijing Hospital of Digestive Diseases

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalNot yet recruiting

Upper Gastrointestinal Bleeding

NCT07749300

Clinical

Trials by Indication[1]

Esophagitis1 trial

Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole

Withdrawn·XXijing Hospital of Digestive Diseases·Phase 4·NCT02986685

Post Operative Nausea and Vomiting1 trial

Study of Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)for Treatment of Post Operative Nausea and Vomiting

Unknown status·—·Phase 3·NCT01984931·45 enrolled

Upper Gastrointestinal Bleeding1 trial

Role of Trimebutine Maleate in Enhancing Endoscopic Gastric Visualization in Patients With Acute Upper Gastrointestinal Bleeding: A Double-Blind Randomized Controlled Trial

Not yet recruiting·AAssiut University·Preclinical·NCT07749300·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Trimebutine Maleate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Trimebutine Maleate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Trimebutine Maleate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xijing Hospital of Digestive Diseases company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: XXijing Hospital of Digestive Diseases

Trimebutine Maleate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Esophagitis1 trial

Post Operative Nausea and Vomiting1 trial

Upper Gastrointestinal Bleeding1 trial

References

Drug Info

Quick Facts

Related News